Search Results
Your search for ,WHo matches 20933 pages
Showing 13501 - 13550Can Antiviral Therapy Prevent Liver Cancer in Patients With Chronic Hepatitis?
Chronic viral hepatitis is a major causative factor for hepatocellular carcinoma, but antiviral therapy might reduce the incidence of hepatocellular carcinoma by preventing or eliminating chronic hepatitis infections, according to Adrian M. Di Bisceglie, MD, Professor of Internal Medicine at Saint ...
Osimertinib in EGFR Inhibitor–Pretreated T790M-Positive Advanced NSCLC
In the phase II extension component of the phase I/II AURA trial, reported by Yang et al in the Journal of Clinical Oncology, osimertinib (Tagrisso) was found to be highly active in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor–pretreated T790M-positive advanced...
Neoadjuvant Dual HER2 Blockade in HER2-Enriched Early Breast Cancer
In the Spanish phase II PAMELA study reported in The Lancet Oncology, Llombart-Cussac et al found that the HER2-enriched subtype was associated with the highest likelihood of pathologic complete response after neoadjuvant trastuzumab (Herceptin) and lapatinib (Tykerb) without chemotherapy in...
Clinical Trials Actively Recruiting Patients With Colorectal Cancer
Phase I Study Title: A Pilot Study of SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine and Cyclophosphamide in Metastatic Colorectal Cancer as Maintenance Therapy Study Type: Phase I/interventional/parallel assignment Study Sponsor and Collaborators: Sidney Kimmel Comprehensive...
Expect Questions About the Cervical Cancer Mortality Study
A widely reported study found that cervical cancer mortality was higher and the racial disparity between black and white women greater than previously reported.1 The study omitted from the mortality estimates those women who had undergone hysterectomies, usually involving removal of the cervix....
Honoring the Life of Nancy E. Armitage
The University of Nebraska community mourns the loss of dedicated community leader and volunteer Nancy E. Armitage of Omaha. She died February 27, 2017, from complications associated with pancreatic cancer. Nancy is remembered for the support and encouragement she offered to others over the years...
Cervical Cancer Mortality Is Higher and Racial Disparity Wider Than Previously Reported
Cervical cancer mortality rates were significantly higher, particularly among black women, when national data were corrected to exclude women who have had hysterectomies. For black women, the cervical cancer mortality rate rose from 5.7 to 10.1 per 100,000 when corrected for hysterectomy, an...
Immunotherapy for Head and Neck Cancer: ‘The Fourth Modality Has Arrived’
“This is a big deal. This is going to change all of oncology, not just head and neck cancer,”1 Tanguy Seiwert, MD, remarked following a summary by Jeffrey Sosman, MD, on advances in immunotherapy for treating cancer.2 Dr. Sosman, Director of the Melanoma Program and Clinical Director of Cancer...
Immunotherapy Challenges in Lung Cancer: From Patient Selection to Clinical and Financial Toxicity
Immunotherapy has been a major advance in lung cancer, but it is not without its challenges, according to Sanjay Popat, PhD, FRCP, a consultant medical oncologist and reader in cancer medicine at the Royal Marsden Hospital, London, UK. He reviewed some of the challenges pertaining to the use of...
Germline Cancer Susceptibility Mutations in Early-Onset Colorectal Cancer
In a study reported in JAMA Oncology, Pearlman et al found that 16% of patients with early-onset colorectal cancer had germline cancer susceptibility mutations, with a wide array of such mutations being identified. Heather Hampel, MS, CGC, of The Ohio State University Comprehensive Cancer Center,...
Potential Biomarker of Recurrent Venous Thromboembolism in Patients Receiving Anticoagulants
In a biomarker analysis of the CATCH trial reported in the Journal of Clinical Oncology, Alok A. Khorana, MD, of the Cleveland Clinic, and colleagues found that elevated circulating tissue factor levels were associated with an increased risk of recurrent venous thromboembolism in cancer patients on ...
FDA Approves Lenalidomide as Maintenance Therapy for Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
On February 22, the U.S. Food and Drug Administration (FDA) expanded the existing indication for lenalidomide (Revlimid) 10-mg capsules to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant. Clinical Trial Findings The...
No Improvement in Overall Survival With Addition of Ganetespib to Docetaxel in Patients With Non–Small Cell Lung Cancer
Despite positive results in the phase II GALAXY-1 study, the addition of ganetespib to docetaxel in the phase III GALAXY-2 study did not improve overall survival or progression-free survival in patients with advanced non–small cell lung cancer (NSCLC), according to data presented by Rathi Pillai,...
Platinum Study Finds High Risk of Metabolic Syndrome in Testicular Cancer Survivors
A multicenter study of North American testicular cancer survivors treated with platinum-based chemotherapy has found a high prevalence of metabolic syndrome, a cluster of cardiovascular risk factors that doubles the risk of cardiovascular disease.1 According to the results of this trial,...
Building a Multidisciplinary Model of Care for Cancer Survivors
Last year’s inaugural Cancer Survivorship Symposium stressed the importance of bringing together the fields of medical oncology and primary care to ensure a coordinated effort to help patients with cancer transition to long-term survivorship care. Building on that goal, the 2017 Cancer Survivorship ...
Expert Point of View: Selina Luger, MD, Stephanie Lee, MD, and Gabriela Hobbs, MD
Speaking at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, before the hold on pacritinib was lifted (in January 2017), Selina Luger, MD, of the University of Pennsylvania, Philadelphia, commented, “I think the U.S. Food and Drug Administration (FDA) needs to revisit ...
Pacritinib Reduces Spleen Volume in Myelofibrosis
The investigational drug pacritinib met the primary endpoint of the phase III PERSIST-2 trial in high-risk patients with myelofibrosis and thrombocytopenia. Treatment with the Janus kinase (JAK)1/2 inhibitor pacritinib achieved a significant reduction in spleen volume compared with best available...
Cleveland Clinic Opens New Taussig Cancer Center
The new Cleveland Clinic Taussig Cancer Center began welcoming patients on March 6, 2017. The 377,000 square-foot facility houses all outpatient cancer treatment services in one location, with the center’s team of medical and radiation oncologists, surgeons, nurses, genetic counselors, social...
IASLC Statement Regarding Philip Morris’ Smoke-Free Future
On February 1, 2017, the International Association for the Study of Lung Cancer (IASLC) issued the following statement: According to its own public reports, in 2016 Phillip Morris manufactured 800 billion cigarettes. Thus, [IASLC] views with some skepticism Philip Morris’ recent statement...
CAR T-Cell Therapy Emerging in Multiple Myeloma
For patients with multiple myeloma, chimeric antigen receptor (CAR) T-cell therapy is gaining ground in pilot studies. At the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, researchers presented their latest findings for this innovative therapy, which has proven...
Phase III Trial Shows Improved Progression-Free Survival With Fulvestrant vs Anastrozole in Advanced Breast Cancer
In the international phase III FALCON trial, reported in The Lancet, John F.R. Robertson, MD, of the University of Nottingham, United Kingdom, and colleagues found that progression-free survival was improved with intramuscular fulvestrant (Faslodex) vs oral anastrozole in endocrine therapy–naive...
Sandra J. Horning, MD, Received Duane Roth Memorial Award
Sandra J. Horning, MD, Chief Medical Officer and Executive Vice President of Global Development for Roche/Genentech, was named the 2017 recipient of the Duane Roth Memorial Award. The award was presented February 16 at the annual Industry/Academia Translational Oncology Symposium at the University ...
A Decade of Lessons Learned From EGFR-Targeted Therapy
To summarize the lessons learned from the development of epidermal growth factor receptor (EGFR)-targeted therapy, one only has to go back about 10 years, according to Frances A. Shepherd, MD, Scott Taylor Chair in Lung Cancer Research at Princess Margaret Cancer Centre and Professor of Medicine at ...
Study Finds No Evidence of Cytomegalovirus in Glioblastoma and Other High-Grade Gliomas
In a rigorous study of tumor tissue collected from 125 patients with aggressive brain cancers, researchers at Johns Hopkins said they have found no evidence of cytomegalovirus (CMV) infection and concluded that a link between the two diseases, as claimed by earlier reports, likely does not exist. A ...
Late Relapse of Classical Hodgkin Lymphoma in German Hodgkin Study Group Trials
In an analysis of German Hodgkin Study Group trials reported in the Journal of Clinical Oncology, Bröckelmann et al found that the cumulative incidence of late relapse in patients with classical Hodgkin lymphoma was 6.9% at 20 years and that late relapse was more common among those with...
Immunotherapy Combinations Gain Traction in Lung Cancer
Combining immunotherapies with each other or with other agents such as chemotherapy and growth factor inhibitors holds promise for better tapping their benefit in patients with lung cancer, data from several studies suggest. Results show that strategic combinations can achieve higher response...
Update on Overall Survival for Newly Diagnosed Patients With Metastatic Pancreatic Cancer
Although “treatment advances” and “precision medicine” are today’s buzz words in oncology, they don’t apply equally to all malignancies. For instance, median overall survival for newly diagnosed patients with metastatic pancreatic cancer has not improved much over the past 20 years, according to...
No Benefit From Older Standard-of-Care Drug in Adjuvant Chemotherapy for High-Risk Prostate Cancer, but Newer Trials Feasible
An older trial designed to evaluate the benefits of adjuvant therapy following radical prostatectomy in patients with high-risk prostate cancer showed no difference in overall or disease-free survival between 2 years of androgen-deprivation therapy and 2 years of androgen-deprivation therapy plus...
Phase II Trial Evaluates New Gene Therapy for Non–Muscle Invasive Bladder Cancer After BCG
A novel approach using intravesical gene therapy showed promising activity in a phase II trial that enrolled patients with bacillus Calmette-Guérin (BCG)-refractory or -relapsed nonmuscle invasive bladder cancer.1 The rate of high-grade relapse-free survival at 12 months was 35% in patients treated ...
Make Vaccination Great Again
Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide. It affects 80% of individuals, with the initial infection usually occurring between the ages of 15 and 24. Persistent infection with oncogenic HPV genotypes, primarily 16 and 18, is the cause of virtually all...
How Stupid Cancer Is Building a Support Community for AYA Survivors
In 1995, Matthew Zachary, an aspiring concert pianist and composer, was en route to graduate school to study film composition when he lost all fine-motor coordination in his left hand, was diagnosed with pediatric brain cancer (medulloblastoma), told he would never play again, and was given 6...
FALCON Trial Informs the Evolving Role of Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer
Endocrine therapy for breast cancer has evolved over the years. Initial endocrine therapies consisted of ablative procedures (oophorectomy, adrenalectomy, and hypophysectomy). With the availability of pharmaceutical estrogens, progestins, and androgens, ablative procedure utilization begin to...
ASCO Quality Care 2017: Cost and Survival Analysis Before and After Implementation of Clinical Pathways for Patients With Stage IV NSCLC
In a study reported at the 2017 Quality Care Symposium by Zheng et al (Abstract 3) and published in the Journal of Oncology Practice by Jackman et al, researchers explored the use of clinical pathways to support clinical decision-making and manage resources for patients with late-stage...
Financial Stress in Patients With Locally Advanced Head and Neck Cancer
In a single-institution study reported in the Journal of Oncology Practice, de Souza et al found that two-thirds of patients with locally advanced head and neck cancer had to use a financial coping strategy to help pay for care within the first 6 months of treatment. Study Details The study...
Hormone Maintenance Therapy in Low-Grade Serous Cancer of the Ovary or Peritoneum
In a single-institution experience reported in the Journal of Clinical Oncology, Gershenson et al at MD Anderson Cancer Center found that hormonal maintenance therapy was associated with improved progression-free survival among women with stage II to IV low-grade serous carcinoma of the ovary or...
Single Dose of Brachytherapy May Be an Effective Treatment for Localized Prostate Cancer
Results from a new prospective clinical trial indicate that high–dose rate (HDR) brachytherapy administered in a single 19-Gy treatment may be a safe and effective alternative to longer courses of HDR treatment for men with localized prostate cancer. The study was reported by Krauss et al in...
Two Migration Proteins Boost Predictive Value of Pancreatic Cancer Biomarker
Adding two blood-borne proteins associated with cancer cell migration increases the predictive ability of the current biomarker for pancreatic cancer to detect early-stage disease, a research team from The University of Texas MD Anderson Cancer Center reported in a study by Balasenthil et al in the ...
Patients With Cancer History More Likely to Change Prescriptions to Save Money
A new study led by American Cancer Society investigators found that cancer survivors are more likely to change their prescription drug use for financial reasons than those without a cancer history. These findings were published by Zheng et al in Cancer. The rising cost of cancer drugs imposes a...
Poor Diet During Adolescence/Early Adulthood and Risk for Premenopausal Breast Cancer
Although adolescence is a highly susceptible time for mammary carcinogenesis, few prospective studies have examined the role of adolescent diet and breast cancer risk. Now, a study investigating the association of an adolescent and early adulthood dietary pattern that promotes chronic inflammation...
ASCO Quality Care 2017: Mental Health Conditions Contribute to Care-Related Costs, Hospital Visits in Breast and Prostate Cancers
A new analysis of data from the U.S. Military Health System found that mood and adjustment disorders such as anxiety and depression were strong predictors of the annual number of outpatient visits, hospital admissions, and number of days in the hospital for patients with breast and prostate...
ASCO Quality Care 2017: In-House Specialty Pharmacy at Cancer Center Improves Quality of Care, Reduces Medical Errors
An influx of new oral cancer drugs provides patients with a more convenient and less invasive way to take medication, but such treatments are often associated with adherence challenges and medical errors. New research shows that the addition of an in-house specialty pharmacy at a cancer center in...
Effect of Adjuvant Chemoradiotherapy in Resected Locally Advanced Head and Neck Cancer
In a study of National Cancer Database data reported in the Journal of Clinical Oncology, Trifiletti et al found that adjuvant chemoradiotherapy was associated with a survival benefit in patients with resected locally advanced head and neck cancer with negative surgical margins and no extracapsular ...
Leader in Cancer Care and Prevention, Charles A. LeMaistre, MD, Dies
In 1978, Charles A. “Mickey” LeMaistre, MD, was named President of The University of Texas MD Anderson Cancer Center. During his 18-year tenure, MD Anderson became a world leader in outpatient care for cancer patients and the nation’s largest ambulatory treatment and surgery programs in cancers....
Remembering Stephen K. Carter, MD, and His National and International Impact on Early Drug Development
Stephen K. Carter, MD, a renowned oncologist who held a variety of executive positions in the pharmaceutical industry and played a major role in the research and development of many widely used cancer and AIDS drugs, died on November 14, 2016, after a long battle against multiple systems atrophy....
Cancer Has Made Me the Person I Am
My breast cancer diagnosis in 1993, at age 34, came at the happiest moment in my life. I had gotten married just 10 months earlier and was looking forward to the future and children. But instead of celebrating my first wedding anniversary with my husband over a romantic dinner, we were at a cancer ...
Effect of Sorafenib and Hepatitis Status in Advanced Hepatocellular Carcinoma
In a meta-analysis reported in the Journal of Clinical Oncology, Jackson et al found that overall survival with sorafenib (Nexavar) in advanced hepatocellular carcinoma was significantly improved vs comparator treatments among patients who were both hepatitis B virus (HBV)-negative and hepatitis C...
Circulating Tumor DNA as a Prognostic Marker in Pancreatic Cancer
Translational research in pancreatic adenocarcinoma has been limited by the difficulty of obtaining sufficient quality and quantity tumor tissue from patients. A study by Pietrasz et al assessing the feasibility and prognostic value of circulating tumor DNA (ctDNA) in pancreatic adenocarcinoma has...
Rucaparib in Relapsed Platinum-Sensitive High-Grade Ovarian Cancer
In part 1 of the phase II ARIEL2 trial reported in The Lancet Oncology, Elizabeth M. Swisher, MD, of the University of Washington, and colleagues found that the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib was associated with prolonged progression-free survival among patients with...
Assessment of Therapeutic Response by Intrinsic Subtype for HER2-Positive Breast Tumors
In an analysis of outcomes in the North Central Cancer Treatment Group/Alliance N9831 trial reported in the Journal of the National Cancer Institute, Edith A. Perez, MD, of the Mayo Clinic Cancer Center, and colleagues found that patients with tumors scored as HER2-enriched or luminal subtype...
Columbia, NewYork-Presbyterian, and Life Raft Group Form Cancer Research Partnership
Columbia University Medical Center, NewYork-Presbyterian, and the Life Raft Group, a patient advocacy organization specializing in advanced gastrointestinal stromal tumors (GIST), announced that they have entered into a collaborative research project to investigate the efficacy of a novel system...
